Top > Search of International Patents > ANTI-HTLV-1 DRUG AND THERAPEUTIC AGENT FOR HTLV-1-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS (HAM/TSP)

ANTI-HTLV-1 DRUG AND THERAPEUTIC AGENT FOR HTLV-1-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS (HAM/TSP)

Foreign code F180009367
File No. (1705-15P012,S2016-0957-N0)
Posted date Apr 19, 2018
Country WIPO
International application number 2017JP028094
International publication number WO 2018025923
Date of international filing Aug 2, 2017
Date of international publication Feb 8, 2018
Priority data
  • P2016-152871 (Aug 3, 2016) JP
Title ANTI-HTLV-1 DRUG AND THERAPEUTIC AGENT FOR HTLV-1-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS (HAM/TSP)
Abstract Provided are a novel therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and a novel anti-HTLV-1 drug. The therapeutic agent and the anti-HTLV-1 drug comprise, as an active ingredient, a substance capable of inhibiting tyrosine kinase encoded by ABL1 gene.
Outline of related art and contending technology BACKGROUND ART
T lymphocytes tropic viruses-human (hereinafter, HTLV-1) is 1, the genomic DNA of CD4 positive lymphocytes T is incorporated, between the body and individual infected with a retrovirus propagation. HTLV-1 tumor infected cells in adult T cell leukemia can be developed (ATL), the infected cells in the spinal cord HTLV-1 spastic paralysis and dysuria in infiltrating the spinal cord associated with interfering with the spinal disease HTLV-1 (HAM/TSP: HAM HTLV-1-associated myelopathy/tropical spastic paraparesis, may be referred to below) to develop. Further, HTLV-1 in infected cells infiltrating into the eye and uveitis andcorticosteroids (HU).
HTLV-1 above HAM will be due to one of the various diseases, HTLV-1 infected cells in the spinal cord can cause inflammation in the infiltrated except that the trigger, is unknown at development mechanism. Current, with respect to the HAM, and the establishment of a non-therapy to cure, the rate of disease progression in accordance with the magnitude of the inflammation, the treatment is performed to reduce inflammation. Strong inflammation if there is a high possibility to the disease, steroid therapy, interferon, alpha is selected for treatment such as injection therapy, to suppress the inflammation of the spinal cord is prevented from being broken. Specifically, anti-inflammatory agents can include corticosteroids (prednisolone: Predonisolone) oral administration, proviral to reduce the amount of a certain degree, the effect of improving the symptoms have been identified. However, in many cases, the treatment methods, completion of the jig and the like cannot be rebound by the problem of drug withdrawal. Further, the steroid diabetes chiryo method, and immunosuppression may be side effects such as osteoporosis.
As described above, due to HAM HTLV-1, therapeutic for the treatment and cure has been demanded. For example, to Patent Document 1, specifically a human anti-human CXCL10 CXCL10 antibody or antibody fragments, associated with the drugs for the treatment of spinal cord HTLV-1 has been disclosed.
Scope of claims (In Japanese)[請求項1]
ABL1遺伝子によりコードされるチロシンキナーゼを阻害する物質を有効成分とするHTLV-1関連脊髄症(HAM/TSP)治療薬。
[請求項2]
上記物質は、イマチニブ、ニロチニブ及びダサチニブからなる群から選ばれる少なくとも1つの物質であることを特徴とする請求項1記載のHTLV-1関連脊髄症(HAM/TSP)治療薬。
[請求項3]
ABL1遺伝子によりコードされるチロシンキナーゼを阻害する物質を有効成分とする抗HTLV-1剤。
[請求項4]
上記物質は、イマチニブ、ニロチニブ及びダサチニブからなる群から選ばれる少なくとも1つの物質であることを特徴とする請求項3記載の抗HTLV-1剤。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KAGOSHIMA UNIVERSITY
  • Inventor
  • KODAMA Daisuke
  • KUBOTA Ryuji
  • IZUMO Shuji
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close